Core Insights - The company reported a revenue of 609 million yuan for the first three quarters of 2025, representing a year-on-year growth of 2.59%, with a net profit attributable to shareholders of 87 million yuan, up 20.92% year-on-year [1] - In Q3 2025, the company achieved a revenue of 219 million yuan, a year-on-year increase of 9.84%, and a net profit of 33 million yuan, reflecting a significant year-on-year growth of 91.60% [2] Revenue and Profit Performance - The company experienced stable revenue growth in Q3, with profits exceeding expectations, showing continuous improvement since Q2 2025 [2] - The first three quarters of 2025 saw a rapid increase in inquiry volume and new orders, driven by active business development in domestic and international innovative drug transactions [2] Market Development and Client Services - The company has enhanced its market development efforts and accelerated digital transformation to address competitive pressures in the clinical research outsourcing industry [2] - As of the end of Q3 2025, the company employed 4,271 people, with nearly 4,000 being specialized business personnel, serving over 960 clinical trial institutions across 200 cities in China [2] Project Execution and Focus - The company focuses on undertaking innovative and high-clinical-value new drug SMO projects, currently executing 2,538 SMO projects and having completed over 4,200 international and domestic SMO projects [2] Revenue Forecast and Investment Recommendation - Revenue projections for 2025-2027 are estimated at 828 million yuan, 950 million yuan, and 1.107 billion yuan, with year-on-year growth rates of 3.02%, 14.72%, and 16.57% respectively [3] - The net profit attributable to shareholders is forecasted to be 128 million yuan, 144 million yuan, and 164 million yuan for the same period, with corresponding PE ratios of 32, 29, and 25 [3]

Group 1: Company Overview and Financial Performance - Prasis is a data-driven clinical research service provider focused on enhancing clinical trial execution in China, achieving a revenue of CNY 219 million in Q3 2025, a year-on-year increase of 9.84% [2] - For the first three quarters of 2025, the company reported a total revenue of CNY 1.1 billion, reflecting a growth of 6.09%, with a net profit of CNY 87.38 million, up 20.92% [2] - The company distributed cash dividends totaling CNY 5.37 million to shareholders, sharing the development results [2] Group 2: Market Trends and Order Growth - The Chinese innovative drug industry is entering a new phase of high-quality development, driven by policy support and active overseas licensing transactions, leading to a 2.59% increase in new orders [3] - The company has seen a significant increase in new orders from domestic pharmaceutical companies, particularly in oncology projects, which accounted for 39% of global oncology trials in 2024 [3][4] - The number of new projects and contract amounts is expected to grow due to the active overseas licensing collaborations, with over 100 license-out transactions and a total transaction amount exceeding USD 100 billion from January to October 2025 [5] Group 3: Operational Efficiency and Quality Management - The company has implemented a systematic quality management system, including over 280 standard operating procedures (SOPs) and 40 negative lists, ensuring no major findings during inspections by regulatory bodies [7] - Digital transformation initiatives are underway to enhance service efficiency and human resource effectiveness, integrating artificial intelligence and other new technologies [8] - Cost control measures include optimizing organizational structure and enhancing internal performance assessments to improve employee productivity [8] Group 4: Competitive Landscape and Industry Dynamics - The SMO industry is experiencing a concentration of resources towards leading firms, with smaller companies gradually exiting the market due to increased competition and regulatory demands [6] - Large pharmaceutical companies prefer stable, well-networked suppliers capable of managing complex clinical trial projects, which emphasizes the importance of quality and operational capability [6] - The regulatory environment is evolving, with stricter oversight and alignment with international standards, further highlighting the advantages of systematic and standardized operations [6]

Core Viewpoint - The company, Pruis, established in 2013 and listed in 2022, is a leading SMO enterprise in China, specializing in technology development and consulting in the pharmaceutical sector, with a strong project management and quality control capability [1] Financial Performance - In Q3 2025, Pruis achieved a revenue of 609 million yuan, ranking 14th in the industry, significantly lower than the top competitor WuXi AppTec's 32.857 billion yuan and second-place Kanglong Chemical's 10.086 billion yuan [2] - The net profit for the same period was 87.3815 million yuan, also ranking 14th, and below the industry average of 58.5 million yuan [2] Financial Ratios - As of Q3 2025, Pruis had a debt-to-asset ratio of 16.69%, lower than the industry average of 22.79%, indicating good solvency [3] - The gross profit margin was 25.58%, which, while improved from 24.52% year-on-year, remains below the industry average of 37.70% [3] Executive Compensation - The chairman, Lai Chunbao, received a salary of 496,500 yuan in 2024, a decrease from 513,000 yuan in 2023 [4] - The general manager, Yang Hongwei, earned 1.6174 million yuan in 2024, down from 1.6387 million yuan in 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 0.20% to 8,588, while the average number of shares held per shareholder decreased by 0.20% to 8,770.25 [5] - Notable changes among the top ten shareholders include the entry of Noan Pioneer Mixed A as the fifth-largest shareholder and a significant reduction in holdings by Tianhong Medical Health A [5] Business Outlook - According to Changcheng Guorui Securities, Pruis's performance in the first half of 2025 showed improvement, with new orders growing rapidly, including a 40.12% year-on-year increase in new contracts totaling 600 million yuan [5] - The company is expected to see revenue growth, with projected net profits of 121 million yuan, 131 million yuan, and 141 million yuan for 2025 to 2027, respectively [5] - Xinda Securities noted significant improvements in Q2 2025, with a total of 4,157 employees and nearly 4,000 in business roles, serving over 960 clinical trial institutions across more than 200 cities [6] - The company has established a comprehensive quality control system with over 280 SOP documents, maintaining a strong reputation in project execution [6]

Core Insights - The company reported a total revenue of 609 million yuan for Q3 2025, ranking 25th among disclosed peers [1] - The net profit attributable to shareholders was 87.38 million yuan, with a net cash inflow from operating activities of 15.24 million yuan, ranking 31st among peers [1] Financial Metrics - The latest debt-to-asset ratio is 16.69% [3] - The gross profit margin stands at 25.58%, ranking 36th among disclosed peers [3] - The return on equity (ROE) is 6.98% [3] - The diluted earnings per share (EPS) is 1.11 yuan [3] - The total asset turnover ratio is 0.42 times, a decrease of 0.02 times compared to the same period last year, reflecting a year-on-year decline of 3.93% [3] Shareholder Structure - The number of shareholders is 8,588, with the top ten shareholders holding a total of 44.49 million shares, accounting for 56.31% of the total share capital [3] - The top ten shareholders and their respective holdings are as follows: 1. Shihezi Xitai Equity Investment Partnership (Limited Partnership) - 18.71% 2. Shihezi Ruixin Equity Investment Partnership (Limited Partnership) - 8.10% 3. Shihezi Ruizesheng Equity Investment Co., Ltd. - 7.40% 4. Shanghai Guanyu Investment Development Co., Ltd. - 6.93% 5. Lai Chunbao - 6.17% 6. Industrial and Commercial Bank of China - 4.17% 7. Li Weike - 1.33% 8. China Merchants Securities - 1.22% 9. Zhang Jing - 1.16% 10. China Resources Shen Guotou Trust - 1.15% [3]

Core Insights - The company reported a revenue of 609 million yuan for the first three quarters of 2025, representing a year-on-year increase of 2.59% [1] - Net profit reached 87.38 million yuan, showing a year-on-year growth of 20.92% [1] - The company attributed its performance to ongoing refined operational management measures [1] Company Overview - The company is a data-driven clinical research service provider, focusing on the management of clinical trial site organizations (SMO) [1] - It has served over 960 clinical trial institutions and has the capability to cover more than 1,300 institutions across over 200 cities in China [2] - As of the reporting period, the company had undertaken over 4,200 international and domestic SMO projects, with 2,538 projects currently in execution [2] Market Demand and Performance - The company noted a positive recovery in industry and client demand, with a significant increase in inquiry volume and new contracts [1] - The new signed contracts (excluding tax) amounted to 600 million yuan, reflecting a year-on-year increase of 40.12% [2] - The company’s backlog of contracts (excluding tax) stood at 1.998 billion yuan, up 9.45% year-on-year as of June 2025 [2] Industry Landscape - The SMO industry in China is entering a new development phase, with leading SMO companies expanding their client resources, professional talent, and research institution coverage [3] - There is an increasing concentration in the industry as smaller SMO companies begin to exit the market, benefiting larger firms with stronger technical barriers and brand influence [3]

Core Insights - The company reported a revenue of 609 million yuan for the first three quarters of 2025, representing a year-on-year growth of 2.59% [1] - The net profit attributable to shareholders of the listed company was 87.38 million yuan, showing a year-on-year increase of 20.92% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 69.67 million yuan, reflecting a year-on-year growth of 11.48% [1] - The basic earnings per share were 1.11 yuan [1]

Core Viewpoint - The company reported a modest increase in revenue and a significant rise in net profit for the third quarter, indicating a positive financial performance despite a challenging market environment [1] Financial Performance - The company's operating revenue for the first three quarters reached 609 million yuan, representing a year-on-year growth of 2.59% [1] - The net profit attributable to shareholders of the listed company was 87.38 million yuan, showing a year-on-year increase of 20.92% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 69.67 million yuan, reflecting a year-on-year growth of 11.48% [1]

Core Viewpoint - The company reported a modest increase in revenue and a significant rise in net profit for the third quarter, indicating a positive financial performance despite a challenging market environment [1] Financial Performance - The company's operating revenue for the first three quarters reached 609 million yuan, representing a year-on-year growth of 2.59% [1] - The net profit attributable to shareholders for the same period was 87.38 million yuan, showing a year-on-year increase of 20.92% [1] - The net profit after deducting non-recurring gains and losses was 69.67 million yuan, reflecting a year-on-year growth of 11.48% [1]

二、董事会会议审议情况 经与会董事认真审议，一致同意通过如下决议： （一）审议通过《关于公司<2025 年第三季度报告>的议案》 经审议，董事会认为：公司《2025 年第三季度报告》的编制程序符合法律、 行政法规和中国证券监督管理委员会、深圳证券交易所的相关法律法规、规范性 文件的规定，报告内容真实、准确、完整地反映了公司的实际情况，不存在任何 虚假记载、误导性陈述或者重大遗漏。 本议案已经公司董事会审计委员会审议通过。 证券代码:301257 证券简称:普蕊斯 公告编号:2025-063 普蕊斯（上海）医药科技开发股份有限公司 第三届董事会第十六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 普蕊斯（上海）医药科技开发股份有限公司（以下简称"公司"）第三届董事 会第十六次会议于 2025 年 10 月 28 日在公司会议室以现场会议及通讯相结合的 形式召开，本次会议通知及会议资料已于 2025 年 10 月 24 日以专人送达、电子 邮件的方式发出，会议应出席董事 9 人，实际参与会议的董事 9 人，其中董事马 林、刘 ...

证券代码：301257 证券简称：普蕊斯 公告编号：2025-064 普蕊斯（上海）医药科技开发股份有限公司 关于 2025 年前三季度利润分配方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、公司 2025 年前三季度利润分配方案为：以现有公司总股本 79,004,770 股为基数，向全体股东每 10 股派发现金红利 0.68 元（含税），合计派发现金股 利 5,372,324.36 元（含税），本次不进行资本公积转增股本，不送红股。 公司分别于 2025 年 10 月 24 日、10 月 28 日召开了第三届董事会审计委员 会第十四次会议、第三届董事会第四次独立董事专门会议和第三届董事会第十六 次会议，审议通过了《关于 2025 年前三季度利润分配方案的议案》，同意公司 实施 2025 年前三季度利润分配方案。本次利润分配方案在公司 2024 年年度股东 大会授权范围内，无需提交股东会审议。 二、2025 年前三季度利润分配方案基本情况 根据公司 2025 年第三季度财务报告（未经审计），公司 2025 年前三季度实 现归属于上市 ...